Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva to cease US shipments of generic Ortho Tri-Cyclen

This article was originally published in Scrip

Executive Summary

Teva Pharmaceutical Industries has agreed to cease US shipments of its generic version of Johnson & Johnson's Ortho Tri-Cyclen Lo (norgestimate plus ethinylestradiol), pending a preliminary injunction hearing in a related patent infringement case scheduled to begin on July 15th. The move follows a July 1st "at risk" launch of the generic product by Teva after it had gained FDA final approval of its ANDA.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts